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Introduction {#sec001}
============

Shigellosis is very contagious and can spread through communities at a fast rate posing a health threat globally. The low infective dose and the transmissibility of this agent through fingers, flies, fomites, food and faecal contamination of drinking water allows this organism to cause outbreaks very easily \[[@pone.0160290.ref001]\].

Shigellosis can be caused by any of the known serogroups of *Shigella*. But the relative frequency of the isolation of the most common serogroup differs geographically, the most common being *Shigella flexneri* in the developing nations. Though *S*.*sonnei* has been attributed to cause disease mostly in developed countries the current scenario speaks otherwise as it is marked by spread of this agent due to travel to endemic places. Several reports from the Indian subcontinent and south-east Asian countries have revealed a changing scenario regarding the shift in serogroups of *Shigella*. All in common have highlighted the growing importance of *S*.*sonnei* emerging as a close competitor of *S*.*flexneri* in its dominance \[[@pone.0160290.ref002],[@pone.0160290.ref003],[@pone.0160290.ref004]\]. Ciprofloxacin has been an empirical therapy for shigellosis across the globe for a very long time. Resistance to quinolones is mediated by mutations in the chromosomal genes called the quinolone resistance determining regions (QRDRs) of DNA gyrases namely, *gyrA* and *gyrB* and the Type IV topoisomerases namely, *parC* and *parE* or the presence of plasmid genes called the plasmid mediated quinolone resistance regions (PMQRs) namely the *qnr* (*qnrA*, *qnrB*, *qnrC*, *qnrD*, *qnrS*, *qep*, *aac(6')lb-cr*) genes. Drug efflux pumps like *mdfA*,*tolC*,*ydhE*,*marA*. confer quinolone resistance. Any change in the outer membrane leading to porin loss can also result in increase in MIC to quinolones. The emergence of ciprofloxacin resistance has been reported since 2002 with the clonal spread of a ciprofloxacin resistant *S*.*dysenteriae* serotype 1 from Kolkata to other places followed by *S*.*flexneri* 2a and *S*.*flexneri* 3a in 2004 and finally in *S*.*sonnei* in 2007\[[@pone.0160290.ref002]\]. There are increasing reports regarding ciprofloxacin resistant *Shigella* across the globe which can be attributed to increased frequency in international travels, low infective dose and ease of accepting antibiotic resistance genes by horizontal gene transmission \[[@pone.0160290.ref005]\].

The following study was carried out to understand the emergence of *S*.*sonnei* with respect to ciprofloxacin resistance in our patient population.

Materials and Method {#sec002}
====================

The study was reviewed and approved by the Institute Ethics Committee (Human studies) at Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry (Approval No. JIP/IEC/2014/5/324). Since, the samples are collected for routine diagnostics, our hospital does not have a policy for taking informed consent for collecting stool samples from patients. The ethics committee approval was obtained to store and study the microbial isolates obtained from these samples.

*S*.*sonnei* isolated from stool samples at Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India between years 2012 to 2015 were selected for this study. The isolates were obtained from stool samples of diarrhoea and dysentery cases and confirmed by standard biochemical tests \[[@pone.0160290.ref006]\] followed by serotyping by slide agglutination using specific antisera (Denka-Seiken, Tokyo, Japan). Antibacterial susceptibility and minimum inhibitory concentrations (MICs) of the isolates was determined in accordance with the Clinical laboratory standards institute (CLSI) guidelines\[[@pone.0160290.ref007]\] by the Kirby Bauer method and the MICs of quinolones was performed using the E-test(Biomerieux, Etoile, France). The quinolones tested included ciprofloxacin (Cf), ofloxacin (Of) and levofloxacin (Le). ATCC *Escherichia coli* ATCC 25922 was included as control in each test.

Total DNA was extracted from the isolates using the boiling lysis method\[[@pone.0160290.ref008]\]. Briefly, a single colony from overnight culture was suspended in 100microlitre sterile molecular grade water. This preparation was boiled at 100degC for 30minutes followed by flash cooling on ice for 5 minutes. The preparation was then centrifuged at 10000g for 5 minutes and supernatant transferred to a fresh tube and stored at -20degreesC.

Polymerase chain reaction (PCR) based detection of virulence genes (*ipaH*, *sen*, *set1A*, *set1B*, *ial*, *and stx1*) among the isolated *Shigella* spp. was performed using published primers \[[@pone.0160290.ref009],[@pone.0160290.ref010],[@pone.0160290.ref011]\] as described in [Table 1](#pone.0160290.t001){ref-type="table"}. The QRDRs of *gyrA*, *gyrB*, *parC*, and *parE* genes were amplified using published primers ([Table 1](#pone.0160290.t001){ref-type="table"}) as described earlier \[[@pone.0160290.ref012]\]. PCR was performed to amplify PMQR targets for the presence of four major groups of *qnr* determinants, *qnrA*, *qnrB*, *qnrC*, *qnrS* and two additional PMQR genes, *qepA* and *aac(6′)-Ib-cr*, using published primers \[[@pone.0160290.ref013]\] as described in [Table 1](#pone.0160290.t001){ref-type="table"}. All primers used in this study were obtained from Bioserve India biotechnologies India private limited, India.

10.1371/journal.pone.0160290.t001

###### Primers used in this study.

![](pone.0160290.t001){#pone.0160290.t001g}

  GENE                                            SEQUENCE (5'→3')            REFERENCE
  ----------------- ----------------------------- --------------------------- ------------------------
  *gyrA*            FORWARD                       `TACACCGGTCAACATTGAGG`      [@pone.0160290.ref012]
  REVERSE           `TTAATGATTGCCGCCGTCGG`        [@pone.0160290.ref012]      
  *gyrB*            FORWARD                       `TGAAATGACCCGCCGTAAAGG`     [@pone.0160290.ref012]
  REVERSE           `GCTGTGATAACGCAGTTTGTCCGGG`   [@pone.0160290.ref012]      
  *parC*            FORWARD                       `GTCTGAACTGGGCCTGAATGC`     [@pone.0160290.ref012]
  REVERSE           `AGCAGCTCGGAATATTTCGACAA`     [@pone.0160290.ref012]      
  *parE*            FORWARD                       `ATGCGTGCGGCTAAAAAAGTG`     [@pone.0160290.ref012]
  REVERSE           `TCGTCGCTGTCAGGATCGATAC`      [@pone.0160290.ref012]      
  *qnrA*            FORWARD                       `ATTTCTCACGCCAGGATTTG`      [@pone.0160290.ref013]
  REVERSE           `GATCGGCAAAGGTTAGGTCA`        [@pone.0160290.ref013]      
  *qnrB*            FORWARD                       `GATCGTGAAAGCCAGAAAGG`      [@pone.0160290.ref013]
  REVERSE           `ATGAGCAACGATGCCTGGTA`        [@pone.0160290.ref013]      
  *qnrC*            FORWARD                       `GGGTTGTACATTTATTGAATCG`    [@pone.0160290.ref013]
  REVERSE           `CACCTACCCATTTATTTTCA`        [@pone.0160290.ref013]      
  *qnrS*            FORWARD                       `GCAAGTTCATTGAACAGGGT`      [@pone.0160290.ref013]
  REVERSE           `TCTAAACCGTCGAGTTCGGCG`       [@pone.0160290.ref013]      
  *aac(6′)-Ib-cr*   FORWARD                       `TTGCGATGCTCTATGAGTGGCTA`   [@pone.0160290.ref013]
  REVERSE           `CTCGAATGCCTGGCGTGTTT`        [@pone.0160290.ref013]      
  *qepA*            FORWARD                       `AACTGCTTGAGCCCGTAGAT`      [@pone.0160290.ref013]
  REVERSE           `GTCTACGCCATGGACCTCAC`        [@pone.0160290.ref013]      
  ERIC              FORWARD                       `ATGTAAGCTCCTGGGGATTCAC`    [@pone.0160290.ref015]
  REVERSE           `AAGTAAGTGACTGGGGTGAGCG`      [@pone.0160290.ref015]      
  *ipaH*            FORWARD                       `TGGAAAAACTCAGTGCCTCT`      [@pone.0160290.ref009]
  REVERSE           `CCAGTCCGTAAATTCATTCT`        [@pone.0160290.ref009]      
  *sen*             FORWARD                       `ATGTGCCTGCTATTATTTAT`      [@pone.0160290.ref011]
  REVERSE           `CATAATAATAAGCGGTCGC`         [@pone.0160290.ref011]      
  *ial*             FORWARD                       `CTGGATGGTATGGTGAGG`        [@pone.0160290.ref011]
  REVERSE           `GGAGGCCAACAATTATTTCC`        [@pone.0160290.ref011]      
  *stx1*            FORWARD                       `CTGGATTTAATGTCGCATAGTG`    [@pone.0160290.ref010]
  REVERSE           `AGAACGCCCACTGAGATCATC`       [@pone.0160290.ref010]      
  *set1A*           FORWARD                       `TCACGCTACCATCAAAGA`        [@pone.0160290.ref011]
  REVERSE           `TATCCCCCTTTGGTGGTA`          [@pone.0160290.ref011]      
  *set1B*           FORWARD                       `GTGAACCTGCTGCCGATATC`      [@pone.0160290.ref011]
  REVERSE           `ATTTGTGGATAAAAATGACG`        [@pone.0160290.ref011]      

PCR amplified products were then subjected to sequencing using an ABI 3700 sequencer (Applied Biosystem, Foster, CA, USA) at Bioserve India biotechnologies India private limited, India. Contig sequences generated were assembled and compared using the Basic Local Alignment Search Tool (BLAST) of the NCBI.

Drug accumulation assay was performed as described earlier \[[@pone.0160290.ref014]\]. Briefly, ciprofloxacin sensitive and resistant isolates of *Shigella* were grown in LB and harvested. The MIC of ciprofloxacin was determined on Mueller Hinton agar with and without Carbonyl cyanide m-chlorophenylhydrazone (CCCP) at a concentration of 20 mg/L using the Etest (Biomerieux, Etoile, France). A reduction in the MIC by 2--4 fold indicated the presence of an efflux pump activity.

ERIC PCR was performed according to Ranjbar et al \[[@pone.0160290.ref015]\] with some minor modifications viz. the gel electrophoresis was performed at 80 V for 1 hour instead of 4 hours. The ERIC-PCR profiles were normalized and analysed by PyElph (which is an open source Python based software for gel images analysis).

Results {#sec003}
=======

Of the 184 *Shigella* sp. isolated *S*.*flexneri* was the maximum (95/184 = 51.7%), followed by *S*.*sonnei*(34/184 = 20.6%),*S*.*dysenteriae*(7/184 = 3.7%),*S*.*boydii*(6/184 = 3.1%)and non-typable *Shigella*(42/184 = 22.2%). The year wise number of isolates are as mentioned in [Table 2](#pone.0160290.t002){ref-type="table"}.

10.1371/journal.pone.0160290.t002

###### Isolation of different serogroups during the period of study (2012--2015).

![](pone.0160290.t002){#pone.0160290.t002g}

  Year    *S*.*dysenteriae*   *S*.*flexneri*   *S*.*boydii*   *S*.*sonnei*   [\*](#t002fn001){ref-type="table-fn"}NT*Shigella*   Total
  ------- ------------------- ---------------- -------------- -------------- --------------------------------------------------- -------
  2012    0                   21(55.26)        1(2.63)        5(1.31)        11(28.94)                                           38
  2013    3(7.31)             20(48.78)        1(2.43)        11(26.8)       6(14.63)                                            41
  2014    1(1.88)             24(45.28)        1(1.88)        13(24.52)      14(26.41)                                           53
  2015    3(5.76)             30(57.69)        3(5.76)        5(9.61)        11(21.15)                                           52
  Total   7(3.80)             95(51.63)        6(3.26)        34(18.47)      42(22.82)                                           184

\* NT: non-typable

Of the 34 isolates in our study, the invasive plasmid gene *ipaH* was found in all the isolates followed by the invasion associated locus gene *ial* in 17.6% of isolates and *sen* in (11.7%). The *Shigella* enterotoxin genes *set1A*&*set1B*were found in 5.8% of the isolates. No *stx1* element was found among the isolates studied.

Of the 34 isolates studied, 16 showed resistance to fluoroquinolones namely, ciprofloxacin, levofloxacin and ofloxacin. The MICs of 16/34 quinolone resistant isolates tested ranged from 4micrograms/ml to 16micrograms/ml for ciprofloxacin, from 16 micrograms/ml to 64 micrograms/ml for ofloxacin and from 16micrograms/ml to 64micrograms/ml for levofloxacin.

Sequence determination of the QRDRs of *gyrA*, *gyrB*, *parC*, and *parE*genes showed mutations in GyrA and in ParC. The various mutations detected are as shown in [Table 3](#pone.0160290.t003){ref-type="table"}. Fisher's Exact test and Chi square test did not correlate with the presence of mutation of amino acids and high MIC of 16micrograms/ml (p value = 0.518).

10.1371/journal.pone.0160290.t003

###### Detailed description of the virulence profile, antibiotic resistance profile, MIC of the quinolones tested, efflux pump assay, PMQRs, mutation analysis of the QRDRs and ERIC types.

![](pone.0160290.t003){#pone.0160290.t003g}

  Sl.no   Isolate no   Virulence gene profile   Antibiotic resistance pattern   MIC values (micrograms/ml)   MIC values (micrograms/ml) of Cf with efflux pump inhibitor   MIC values (micrograms/ml) of Cf without efflux pump inhibitor   Antibiotic resistance gene profile   Mutation analysis   ERIC type by NJ                                                                                                                                 
  ------- ------------ ------------------------ ------------------------------- ---------------------------- ------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------ ------------------- ----------------- ------- ------- ------- ------- ---- ---- ---- ---- ---- ---- ------------------------------------------ ---- ---------- ---- -----
  1       S1/12        \-                       \-                              \-                           \-                                                            \+                                                               \-                                   A/NA/CO             0.75              0.19    0.38    0.38    0.38    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  2       S93/12       \-                       \-                              \-                           \-                                                            \+                                                               \-                                   NA/CO               0.5               0.25    0.75    0.75    0.75    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  3       S95/12       \-                       \-                              \-                           \-                                                            \+                                                               \-                                   NA/CO               0.75              0.75    0.25    0.25    0.25    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  4       S247/13      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF/CO               16                16      8       4       8       \-   \+   \-   \-   \-   \-   106 (H→P)                                  \-   \-         \-   I
  5       S390/13      \-                       \-                              \+                           \-                                                            \+                                                               \-                                   A/CF/CO             32                32      16      8       16      \-   \+   \-   \-   \-   \-   72 (S→P)75 (M→L)94 (M→L)106(H→P)           \-   64 (A→D)   \-   I
  6       S391/13      \-                       \-                              \+                           \+                                                            \+                                                               \-                                   A/CF/CO             32                32      16      4       16      \-   \+   \-   \-   \-   \-   69 (Q→W)71 (F→S)90 (S→C)161(N→H)163(T→A)   \-   \-         \-   II
  7       S415/13      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   A/CO(I)             0.38              0.5     0.75    0.75    0.75    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   IV
  8       S715/13      \+                       \+                              \+                           \+                                                            \+                                                               \-                                   A/CF/CO             16                16      4       6       4       \-   \-   \+   \-   \-   \-   72(S→P)                                    \-   \-         \-   I
  9       S750/13      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CO                  0.75              0.5     0.125   0.125   0.125   \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  10      S839/13      \+                       \+                              \+                           \-                                                            \+                                                               \-                                   A/CO                1                 0.75    0.5     0.5     0.5     \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   I
  11      S774/14      \-                       \-                              \+                           \-                                                            \+                                                               \-                                   CO                  0.75              0.75    0.38    0.38    0.38    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  12      S604/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF/CO               64                64      8       4       8       \-   \+   \-   \-   \-   \-   \-                                         \-   \-         \-   IV
  13      S353/13      \-                       \-                              \-                           \+                                                            \+                                                               \-                                   CO                  32                32      16      4       16      \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   IV
  14      S190/13      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CO(I)               0.5               1       0.19    0.19    0.19    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   IV
  15      S432/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF/CO               32                32      16      4       16      \-   \+   \-   \-   \-   \-   90 (S→C)                                   \-   \-         \-   II
  16      S587/12      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CO                  0.38              0.5     0.125   0.125   0.125   \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   IV
  17      S187/12      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF/NA/CO            16                16      4       4       4       \-   \+   \-   \-   \-   \-   \-                                         \-   \-         \-   IV
  18      S359/13      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF                  32                32      16      4       16      \-   \+   \-   \-   \-        69(Q→W)                                    \-   \-         \-   IV
  19      S163/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CO                  0.094             0.094   0.38    0.38    0.38    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   II
  20      S463/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CO                  0.38              0.38    0.75    0.75    0.75    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   IV
  21      S523/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CO                  0.75              0.75    0.38    0.38    0.38    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   IV
  22      S367/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF/CO               32                32      16      4       16      \-   \+   \-   \-   \-   \-   75(M→L)                                    \-   \-         \-   II
  23      S385/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CO                  0.38              0.38    0.25    0.25    0.25    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   II
  24      S404/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   A/CF/CO             16                16      4       4       4       \-   \+   \-   \-   \+   \-   71(P→S)                                    \-   \-         \-   II
  25      S448/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF/CO               32                32      16      4       16      \-   \+   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  26      S798/14      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   Nil                 0.38              0.5     0.75    0.75    0.75    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  27      S409/14      \-                       \-                              \+                           \+                                                            \+                                                               \-                                   CF/CO               32                32      16      4       16      \-   \+   \-   \-   \+   \-   90 (S→C),161(A→H)                          \-   \-         \-   III
  28      S800/13      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   A/CO                0.38              0.38    0.75    0.75    0.75    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  29      S427/15      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   A/CF/CO             32                32      16      4       16      \-   \+   \-   \-   \-   \-   69 (Q→W)                                   \-   \-         \-   III
  30      S442/15      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   A/CF/CO             32                32      16      16      16      \-   \+   \-   \-   \-   \-   71 (F→S)163 (T→A)                          \-   \-         \-   III
  31      S511/15      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF/CO               32                32      16      4       16      \-   \+   \+   \-   \-   \-   75 (M→L)161 (N→H)                          \-   \-         \-   III
          S548/15      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CF/CO               32                32      16      16      16      \-   \+   \+   \-   \-   \-   72 (S→P)161 (N→H)163 (T→A)                 \-   \-         \-   III
  33      S608/15      \-                       \-                              \-                           \-                                                            \+                                                               \-                                   CO                  0.125             0.125   0.25    0.25    0.25    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  34      S1068/14     \-                       \-                              \-                           \-                                                            \+                                                               \-                                   A/CO                0.38              0.38    0.75    0.75    0.75    \-   \-   \-   \-   \-   \-   \-                                         \-   \-         \-   III
  35      ATCC 25922   ND                       ND                              ND                           ND                                                            ND                                                               ND                                   Nil                 0.032             0.032   0.012   0.012   0.012   ND   ND   ND   ND   ND   ND   ND                                         ND   ND         ND   ND

ND = Not done; Le = Levofloxacin; Of = Ofloxacin; Cf = Ciprofloxacin; CCCP = Carbonyl cyanide m-chlorophenylhydrazone (CCCP); NJ = Neighbour joining; H = Histidine; P = Proline; S = Serine; M = Methionine; L = Leucine; Q = Glutamine; W = Tryptophan; F = Phenyalanine; C = Cysteine; N = Asparagine; T = Threonine; A = Alanine

Among the PMQR genes,*qnrB* was the most prevalent, seen in 93.7% of the ciprofloxacin resistant isolates while, *qnrC* was positive in 18.7%. None harboured *qnrA* and *qnrS*. Two (0.1%) of the isolates were positive for *aac(6')-lb-cr*gene. The *qepA* gene regulating the efflux pump was negative in all the isolates studied ([Fig 1](#pone.0160290.g001){ref-type="fig"}). Drug accumulation assay detected the presence of efflux pump activity in 9/15 (60%) among ciprofloxacin resistant isolates which showed fourfold decrease in MIC after the addition of CCCP. Spearman rank correlation coefficient and regression coefficient between PMQR gene and MIC of ciprofloxacin did not show any correlation.

![Distribution of Plasmid mediated quinolone resistance genes.](pone.0160290.g001){#pone.0160290.g001}

None of the quinolone sensitive isolates harboured any of the PMQR genes. Though *gyrA*,*gyrB*, *parC*, *parE* was detected by PCR in them but none showed any mutation.

All isolates were typable by ERIC-PCR. The ERIC PCR amplified DNA fragments ranged from 200 to 2500 bp. The number of bands produced ranged from 2 to 8, which were included in the statistical analysis because the bands were distinct in this region. The statistical analysis of the ERIC-PCR DNA fingerprints was performed with the PyElph graphic user interface program using hierarchical cluster analysis (Neighbour-joining method). ERIC--PCR analysis of the isolates resulted in four major ERIC groups (Table A in [S1 File](#pone.0160290.s001){ref-type="supplementary-material"}; [Fig 2](#pone.0160290.g002){ref-type="fig"}) labelled ERIC group I, II, III and IV. Type III was the dominant type (15/34 = 44.1%) followed by type IV(8/34 = 23.5%), type II and then type I(4/34 = 11.8%).

![Phylogenetic tree using Neighbour joining method for ERIC pattern of *S*.*sonnei*.](pone.0160290.g002){#pone.0160290.g002}

Discussion {#sec004}
==========

During the study period, *S*.*flexneri* remained the most dominant serogroup, as documented earlier \[[@pone.0160290.ref016],[@pone.0160290.ref017]\]. The closest serogroup following this was the *S*.*sonnei* which showed a steep rise in 2013, maintaining a plateau till 2014 and then saw a downward trend ([Table 2](#pone.0160290.t002){ref-type="table"}).

All the isolates had the *ipaH* gene with a variability in the presence of the other virulence genes namely, *ial*and *sen*. Overall, nearly 6% (3/34) of the isolates harboured both the *set1A* and *set1B* genes. The presence of *set 1A* is a very unusual finding in these isolates as this gene is not known to be present in this serogroup \[[@pone.0160290.ref018],[@pone.0160290.ref019]\]. This enterotoxin gene is known to be present only in *S*.*flexneri*. Dissemination of this gene among the different serogroups needs to be studied in detail, though this unusual phenomenon could be attributed to horizontal gene transmission (HGT). Evidence for the presence of *set1A* and *set1B* genes in all *S*.*flexneri* in our sample population has been documented in an earlier published report \[[@pone.0160290.ref008]\]. HGT is well known in *Shigella* due to its genomic plasticity and the presence of mobile genetic elements which have been found very frequently in its megaplasmid. These 3 isolates showing the presence of *set1A* and *set1B* were isolated from 3 different patients, none of whom had any notable severity of infection.

Dysentery was noted in 24/34(70.58%) of the patients in the study group, while the remaining had complaints of watery diarrhoea. Of this 24, *ial* was detected in 2 (8.34%), *sen* in 3(12.5%), *set1A* and *set1B* in 1(4.16%) while *ipaH* was present in all. None of our isolates had *stx1*. A recent study from the USA reported *S*.*sonnei* producing Stx1 with clinical manifestations of bloody diarrhoea in the patients, suggesting a possible role of Stx1 with increased the risk of bloody diarrhoea in these patients \[[@pone.0160290.ref020]\]. Shiga toxin binds to the Gb3 receptors which are concentrated in the vascular endothelium, kidneys and brain but cannot act on the normal intestinal epithelium due to the absence of these receptors \[[@pone.0160290.ref021]\]. Contrarily, it can act on the malignant epithelium since it expresses Gb3 receptors\[[@pone.0160290.ref022]\].

In the present study we observed that 16(47.05%) were resistant to ciprofloxacin by the disc diffusion method and all these had high MIC of ciprofloxacin. All the 8 *S*.*sonnei* isolates from 2008 to 2011 were sensitive to ciprofloxacin, the difference being statistically significant(P value = 0.0159) (Table B in [S1 file](#pone.0160290.s001){ref-type="supplementary-material"}).

Meanwhile, we found that the MIC of all the other quinolones tested were also high in the isolates studied. Our findings are in concordance with those reported elsewhere \[[@pone.0160290.ref023],[@pone.0160290.ref024]\] but unlike a recent study from Andamans, which had shown the MICs to be very high. This finding could be partly because of the presence of efflux pumps in some (27.27%) of these isolates \[[@pone.0160290.ref014]\]. The drug accumulation assay showed that majority (60%) possessed efflux pump activity, which may have additionally contributed to the increased MIC in our isolates. Further, an in-depth assessment in terms of detection and expression of efflux pumps like the *mdfA*, *tolC*, *ydhE*, *marA* etc., remains to be carried out.

We noted a few amino acid substitutions in the protein sequence of *gyrA* ([Table 3](#pone.0160290.t003){ref-type="table"}). Mutations at multiple sites in *gyrA* lead to a higher increment in MIC of ciprofloxacin \[[@pone.0160290.ref025]\]. We did not find any mutation in *gyrB*. This has been documented earlier that majority of the mutations in clinical isolates have been detected in *gyrA* than *gyrB* \[[@pone.0160290.ref026]\]. We also detected mutation affecting a single amino acid in *parC*. It is noteworthy that the MIC is dependent on the specific amino acid substituted and the quinolone susceptibility is altered if a different amino acid is substituted at the same codon position \[[@pone.0160290.ref026]\]. Contrary to the usually reported mutations in GyrA Ser83 and Asp87 positions \[[@pone.0160290.ref027]\], we found novel mutations in the breakage reunion domain of GyrA which is known to be located between residues 67 to 106 ([Table 3](#pone.0160290.t003){ref-type="table"}). Then we found two other mutations outside this domain which have not been reported elsewhere ([Table 3](#pone.0160290.t003){ref-type="table"}). The most common mutation in ParC has been reported at Ser84 position but we found a mutation at position 64 ([Table 3](#pone.0160290.t003){ref-type="table"}). These mutations accumulate in a step wise manner contributing to increase in MIC. Mutations were detected only in *gyrA* and *parC* but not in *gyrB* and *parE* in the ciprofloxacin resistant isolates. These are housekeeping genes and their mere presence do not signify anything and therefore it is important to look for mutations in these regions for quinolone resistance.

Among the PMQR genes, *qnrB* was the most prevalent in our study which is in concordance with earliest reports \[[@pone.0160290.ref028],[@pone.0160290.ref029]\] while in contrast to results of other studies\[[@pone.0160290.ref030]\]. None of our isolates had *qepA*, which is a plasmid mediated efflux pump and *aac(6')-lb-cr* gene which corresponds to aminoglycoside acetyl transferase. Qnr proteins by themselves contribute to the increase in MIC but also facilitate in selecting chromosomal mutants during therapy with a quinolone \[[@pone.0160290.ref028]\]. The MIC of ciprofloxacin did not correlate with the presence of the PMQR genes or the mutations in the QRDRs.

ERIC PCR has been found to be a practically useful alternative typing technique to PFGE for *Shigella* in small laboratories in developing countries. The major advantages are its simplicity, lesser turnaround time, cost per strain is less and need for specialized laboratory equipment is also less, besides, the results of ERIC PCR being comparable to that of PFGE \[[@pone.0160290.ref031],[@pone.0160290.ref032]\]. To understand the degree of relatedness and look for any clustering among the isolates studied, ERIC PCR was performed in this study which resulted in 4 unique clusters, of which Type III was found to be of the most dominant with 44% of the isolates. The relative frequency of the ERIC type differed year wise. ERIC types III and II were significantly (p value 0.016) associated with high MIC of ciprofloxacin(16 micrograms/ml).

Foodborne associated outbreaks of *S*.*sonnei* were reported from Kerala and Maharashtra in 2009 and 2010, where clonal spread was observed with little difference in their pulse types \[[@pone.0160290.ref024]\]. In the year 2015, there were a few reports on outbreaks of ciprofloxacin-resistant *S*.*sonnei* from the USA and Korea \[[@pone.0160290.ref020], [@pone.0160290.ref023]\]. These outbreaks were due to travel into endemic areas where such infections are prevalent and also within day care centre contacts.

Conclusions {#sec005}
===========

Various mechanisms contribute to resistance, there being an occasional difference in the dominance of one over the other and it is not mandatory that all the mechanisms operate in a single strain at any given time. The horizontal transfer of plasmids carrying quinolone resistance determinants, the accumulation of chromosomal mutations and efflux pump played an important role in increasing rates of resistance in our isolates.

The study reflects the emergence of *S*.*sonnei* and quinolone resistance in them documented by the presence of novel mutations in target regions of the QRDRs. In addition, the presence of PMQR genes and efflux pump activity were also noted. The acquisition of an additional virulence gene found otherwise only in *S*.*flexneri* is an intriguing finding which may be reflective of a pathogen driven continuous evolutionary effort to adapt to the natural host environs. Hence alternative strategies aimed at disarming the bacteria by blocking their virulence rather than killing them or preventing their growth need to be developed.
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